睿知中国医院研究地图
候选清单

正在招募肝细胞癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma

ClinicalTrials.gov 上登记的一项肝细胞癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心复旦大学附属中山医院Zhongshan Hospital, Fudan University上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06986785,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Patients with advanced HCC confirmed by histology or cytology;

    入选标准第 5 条

    If hepatitis B virus infection is negative or positive, the status of HBV surface antigen (HBsAg) should be confirmed by HBV serological test;

    入选标准第 15 条

  3. The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0;

    入选标准第 9 条

    Received anti-tumor therapy such as chemotherapy, radiotherapy and biological therapy within 4 weeks before the first use of study drug;

    排除标准第 3 条

    The cumulative dose of anthracyclines > 360 mg/m2 in previous (new) adjuvant therapy;

    排除标准第 21 条

  4. ECOG score was 0-1;

    入选标准第 8 条

  5. Coagulation function: international normalized ratio (INR) ≤1.5×ULN, and activated partial thromboplastin time (APTT) ≤1.5×ULN;

    入选标准第 12 条

  6. At least one measurable lesion meeting the RECIST v1.1 definition was required;

    入选标准第 7 条

  7. Other malignant tumors within 5 years before the first treatment;

    排除标准第 9 条

  8. Pregnant or lactating women;

    排除标准第 22 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义)。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06986785,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Sign the informed consent form voluntarily and follow the protocol requirements;
  2. Gender is not limited;
  3. Age ≥18 years old and ≤75 years old;
  4. Expected survival time ≥3 months;
  5. Patients with advanced HCC confirmed by histology or cytology;
  6. Consent to provide archived tumor tissue samples or fresh tissue samples from the primary or metastatic lesions;
  7. At least one measurable lesion meeting the RECIST v1.1 definition was required;
  8. ECOG score was 0-1;
  9. The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0;
  10. No severe cardiac dysfunction, left ventricular ejection fraction ≥50%;
  11. Organ function level must meet the requirements;
  12. Coagulation function: international normalized ratio (INR) ≤1.5×ULN, and activated partial thromboplastin time (APTT) ≤1.5×ULN;
  13. Urinary protein ≤2+ or ≤1000mg/24h;
  14. No cirrhosis or only Child-Pugh A cirrhosis;
  15. If hepatitis B virus infection is negative or positive, the status of HBV surface antigen (HBsAg) should be confirmed by HBV serological test;
  16. For premenopausal women of childbearing potential, a pregnancy test must be performed within 7 days before the start of treatment, a serum or urine pregnancy test must be negative, and the patient must not be lactating; All enrolled patients should take adequate barrier contraception during the entire treatment cycle and for 6 months after the end of treatment.

排除标准:Exclusion Criteria:

  1. Patients with active central nervous system metastases;
  2. Who had participated in any other clinical trial within 4 weeks before the trial dose;
  3. Received anti-tumor therapy such as chemotherapy, radiotherapy and biological therapy within 4 weeks before the first use of study drug;
  4. Had undergone major surgery (investigator-defined) within 4 weeks before the first dose;
  5. Systemic corticosteroids or immunosuppressive therapy is required within 2 weeks before study dosing;
  6. Pulmonary disease defined as ≥ grade 3 according to NCI-CTCAE v5.0; A history of ILD/pulmonary inflammation requiring steroid treatment;
  7. Serious systemic infection within 4 weeks before screening;
  8. Patients at risk for active autoimmune disease or with a history of autoimmune disease;
  9. Other malignant tumors within 5 years before the first treatment;
  10. Human immunodeficiency virus antibody positive, active tuberculosis or hepatitis C virus infection;
  11. Poorly controlled hypertension by two antihypertensive drugs with different mechanisms;
  12. Diabetic patients with poor glycemic control;
  13. Had a history of severe cardiovascular and cerebrovascular diseases;
  14. Previous history of autologous or allogeneic stem cell, bone marrow or organ transplantation;
  15. Subjects with clinically significant bleeding or significant bleeding tendency within the previous 4 weeks were screened;
  16. Patients with massive or symptomatic effusions or poorly controlled effusions;
  17. Imaging examination showed that the tumor had invaded or wrapped around the chest, neck, pharynx and other large arteries or invaded the pericardium and heart;
  18. Unstable thrombotic events requiring therapeutic intervention within 6 months before screening;
  19. Prior treatment with an ADC drug with a topoisomerase I inhibitor as a toxin;
  20. Patients with a history of allergy to recombinant humanized antibodies or to any excipients of the trial drug;
  21. The cumulative dose of anthracyclines > 360 mg/m2 in previous (new) adjuvant therapy;
  22. Pregnant or lactating women;
  23. Who have a history of psychotropic drug abuse and cannot quit or have mental disorders;
  24. Other conditions for trial participation were not considered appropriate by the investigator.

引自 ClinicalTrials.gov, NCT06986785, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06986785,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06986785